|Author||: Benjamin Bonavida|
|Publisher||: Academic Press|
|Release Date||: 2020-11-02|
|ISBN 10||: 0128226366|
|Pages||: 360 pages|
YY1 Is Pivotal in the Control of the Pathogenesis and Drug Resistance of Cancer: A Critical Therapeutic Target describes the current state-of-the-art of the transcription factor YY1 that is overexpressed in the majority of cancers and a central factor that regulates all of the major features and characteristics of human cancers. This book emphasizes the biochemical, molecular and genetic underlying mechanisms by which YY1 regulates its pro-cancerous activities. In addition, it also describes the role of YY1 in the regulation of tumor cell resistance to conventional chemo and immunotherapies and the important role of inhibiting YY1 in cancer. This book is a valuable source for cancer researchers, oncologists and several members of medical and biomedical field who are interested in understanding further the role of YY1 in cancer. Provides a thorough understanding of the underlying mechanisms by which YY1 regulates cancer cell phenotype and unique characteristics Discusses the novel mechanisms of YY1 regulation of tumor cell resistance and means to overcome resistance Encompasses new examples of newly developed non-toxic and selective inhibitors targeting YY1
|Author||: Benjamin Bonavida,Stavroula Baritaki|
|Publisher||: Academic Press|
|Release Date||: 2020-03-02|
|ISBN 10||: 0128196122|
|Pages||: 504 pages|
Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of new therapeutics and their potential in the treatment of highly resistant cancers and metastases. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students. Provides an update from experts in the field on diagnostics, prognostics and therapeutics Brings a clear overview of recent findings and references, as well as summaries, significant molecular pathways, and conclusions in each chapter Provides a general introductory chapter on contributions in the field and a chapter summary, with synthesized findings and a projection of future goals
|Author||: Benjamin Bonavida|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2008-07-31|
|ISBN 10||: 9781597454742|
|Pages||: 420 pages|
This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies.
Molecular Therapies of Cancer comprehensively covers the molecular mechanisms of anti-cancer drug actions in a comparably systematic fashion. While there is currently available a great deal of literature on anti-cancer drugs, books on the subject are often concoctions of invited review articles superficially connected to one another. There is a lack of comprehensive and systematic text on the topic of molecular therapies in cancer. A further deficit in the relevant literature is a progressive sub-specialization that typically limits textbooks on cancer drugs to cover either pharmacology or medicinal chemistry or signal transduction, rather than explaining molecular drug actions across all those areas; Molecular Therapies of Cancer fills this void. The book is divided into five sections: 1. Molecular Targeting of Cancer Cells; 2. Emerging and Alternative Treatment Modalities; 3. Molecular Targeting of Tumor-Host Interactions; 4. Anti-Cancer Drug Pharmacokinetics; and 5. Supportive Therapies.
Metastasis of cancer cells from primary tumor site to secondary locations is considered a late event in multistep tumorigenesis, and causes most cancer-related mortality. The process from the spreading of cancer cells to the seeding of newly formed tumor colonizations is governed by sequential events, including local invasion, intravasation into stroma and blood vessels, survival in circulation, extravasation, and colonization at secondary tumor sites. Cancer research provides information on the fate of metastatic cancer cells in each sequential movement or heterogeneous tumor microenvironment. However, the complexity of this mechanism remains the most stringent concept of cancer management. This book provides information for cancer researchers on metastatic phenotypes of cancer cells, and diverse promoting factors and molecular mechanisms of metastasis.
This book was conceived from a simple question as to why cancer is so difficult to treat. Ultimately we want to find ways to cure cancers, but that may be an elusive dream at least with the technologies we have now and expect to have in the near future. This leads the question of whether it is possible to improve current cancer treatment methods, especially from the perspective of enhancing targeted drug delivery to tumors. This volume is designed to provide information related to the difficulties in treating cancers through targeted drug delivery, our current understanding of cancer biology, and potential technologies that might be used to achieve enhanced drug delivery to tumors. An ideal drug delivery system for treating cancers would maximize the therapeutic efficacy with minimal side effects in clinical applications. The seemingly improved anticancer efficacy of the current nanoparticle-based formulations needs to be viewed from the context of very poor success rates for translation to human applications. The results of in vitro cell culture models and small animal in vivo experiments have not been extrapolated to clinical applications. Finding the reasons for the lack of successful translation is required if we are to discover approaches to substantially extend the survival time of cancer patients, and hopefully identify cures. Cancer Targeted Drug Delivery: Elusive Dream describes some answers of achieving the so far elusive dream of treating cancers like other chronic diseases with therapies that focus using improved drug delivery systems designed to better align with the unique biological and physiological properties of cancer.
The collection of chapters in this proceeding volume reflects the latest research presented at the Aegean meeting on Tumor Microenvironment and Cellular Stress held in Crete in Fall of 2012. The book provides critical insight to how the tumor microenvironment affects tumor metabolism, cell stemness, cell viability, genomic instability and more. Additional topics include identifying common pathways that are potential candidates for therapeutic intervention, which will stimulate collaboration between groups that are more focused on elucidation of biochemical aspects of stress biology and groups that study the pathophysiological aspects of stress pathways or engaged in drug discovery.
Cancer cell biology research in general, and anti-cancer drug development specifically, still relies on standard cell culture techniques that place the cells in an unnatural environment. As a consequence, growing tumor cells in plastic dishes places a selective pressure that substantially alters their original molecular and phenotypic properties.The emerging field of regenerative medicine has developed bioengineered tissue platforms that can better mimic the structure and cellular heterogeneity of in vivo tissue, and are suitable for tumor bioengineering research. Microengineering technologies have resulted in advanced methods for creating and culturing 3-D human tissue. By encapsulating the respective cell type or combining several cell types to form tissues, these model organs can be viable for longer periods of time and are cultured to develop functional properties similar to native tissues. This approach recapitulates the dynamic role of cell–cell, cell–ECM, and mechanical interactions inside the tumor. Further incorporation of cells representative of the tumor stroma, such as endothelial cells (EC) and tumor fibroblasts, can mimic the in vivo tumor microenvironment. Collectively, bioengineered tumors create an important resource for the in vitro study of tumor growth in 3D including tumor biomechanics and the effects of anti-cancer drugs on 3D tumor tissue. These technologies have the potential to overcome current limitations to genetic and histological tumor classification and development of personalized therapies.
This book focuses on malignant melanoma, discussing the current state of scientific knowledge and providing insights into the underlying basic mechanisms, the molecular changes, genetics and genomics. Human Melanoma is a dangerous type of skin cancer affecting an increasing population, and a better understanding of its development will help in finding sophisticated targeted therapies. The second revised edition features the latest research findings and offers updates on the latest advances and potential novel melanoma therapies. It is a valuable resource for researchers and clinicians working in the fields of melanoma, cancer research and therapy as well as dermatology.
Nutrition and Skeletal Muscle provides coverage of the evidence of dietary components that have proven beneficial for bettering adverse changes in skeletal muscle from disuse and aging. Skeletal muscle is the largest tissue in the body, providing elements of contraction and locomotion and acting as an important contributor to whole body protein and amino metabolism, glucose disposal and lipid metabolism. However, muscle loss, atrophy or weakness can occur when there are metabolic imbalances, disuse or aging. This book addresses the topic by providing insight and research from international leaders, making it the go-to reference for those in skeletal muscle physiology. Provides an understanding of the crucial role of skeletal muscle in global metabolic homeostasis regulation Delivers the information needed to understand the utilization of crucial supplements for the preservation of skeletal muscle Presents insights on research from international leaders in the field
In this Handbook of Experimental Pharmacology on “High Density Lipoproteins – from biological understanding to clinical exploitation” contributing authors (members of COST Action BM0904/HDLnet) summarize in more than 20 chapters our current knowledge on the structure, function, metabolism and regulation of HDL in health and several diseases as well as the status of past and ongoing attempts of therapeutic exploitation. The book is of interest to researchers in academia and industry focusing on lipoprotein metabolism, cardiovascular diseases and immunology as well as clinical pharmacologists, cardiologists, diabetologists, nephrologists and other clinicians interested in metabolic or inflammatory diseases.
With the explosion of information on autophagy in cancer, this is an opportune time to speed the efforts to translate our current knowledge about autophagy regulation into better understanding of its role in cancer. This book will cover the latest advances in this area from the basics, such as the molecular machinery for autophagy induction and regulation, up to the current areas of interest such as modulation of autophagy and drug discovery for cancer prevention and treatment. The text will include an explanation on how autophagy can function in both oncogenesis and tumor suppression and a description of its function in tumor development and tumor suppression through its roles in cell survival, cell death, cell growth as well as its influences on inflammation, immunity, DNA damage, oxidative stress, tumor microenvironment, etc. The remaining chapters will cover topics on autophagy and cancer therapy. These pages will serve as a description on how the pro-survival function of autophagy may help cancer cells resist chemotherapy and radiation treatment as well as how the pro-death functions of autophagy may enhance cell death in response to cancer therapy, and how to target autophagy for cancer prevention and therapy − what to target and how to target it.